MorphoSys to Receive Milestone Payment for CNTO 1959 Phase 2 Program - MarketWatch (press release)

MorphoSys to get Milestone Payment for CNTO 1959 Phase 2 system MarketWatch (press release) MorphoSys AG /quotes/zigman/231105 DE:MOR -1.06% announced today that Janssen Biotech, Inc. (formerly Centocor Ortho Biotech, Inc.) has initiated a phase ii clinical trial in disease of the skin patients with the HuCAL-derived antibody CNTO 1959. ... and more » Link To Article